Subtype
Small Cell Neuroendocrine Carcinoma
CI-CAN-00003964SCNECExplore in graph →
396 active trials6 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003964SCNECExplore in graph →
Clinical trials
1,165 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00213798 | Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients | completed | N/A | 200 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05450965 | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | recruiting | Phase 2 | 37 | University of Maryland, BaltimoreOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06211036 |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab(DeLLphi-305) |
| active not recruiting |
| Phase 3 |
| 563 |
| AmgenINDUSTRY |
| 29 |
| Dec 17, 2025 |
| clinicaltrials |
| NCT07289048 | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT04696575 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT04063163 | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | completed | Phase 3 | 585 | Shanghai Henlius BiotechINDUSTRY | 5 | Dec 9, 2025 | clinicaltrials |
| NCT06758700 | Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07175077 | 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI) | recruiting | — | 20 | University of Missouri-ColumbiaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07244016 | Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC(ES-SCLC) | recruiting | — | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07245446 | A Study of Ivonescimab in First-Line ES-SCLC | recruiting | Phase 2 | 180 | AkesoINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246304 | TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC | recruiting | Early Phase 1 | 24 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03703297 | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy(ADRIATIC) | active not recruiting | Phase 3 | 730 | AstraZenecaINDUSTRY | 19 | Nov 21, 2025 | clinicaltrials |
| NCT05339022 | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial | completed | N/A | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03319940 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | active not recruiting | Phase 1 | 269 | AmgenINDUSTRY | 13 | Nov 19, 2025 | clinicaltrials |
| NCT05588388 | Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases(BELIEVE) | recruiting | Phase 2 | 39 | Kamya SankarOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06283719 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 265 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03672773 | Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04373369 | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 11 | Washington University School of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 1 | 22 | Emory UniversityOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05265429 | Biology of Young Lung Cancer Study: The YOUNG LUNG Study | recruiting | — | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04397003 | Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05468489 | To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC | active not recruiting | Phase 3 | 200 | Shanghai Henlius BiotechINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT03392064 | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC | suspended | Phase 1 | 6 | AmgenINDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04056247 | Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments(PROPHETIC) | active not recruiting | — | 10,000 | OncoHost Ltd.INDUSTRY | 5 | Oct 15, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04472949 | Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | active not recruiting | Phase 2 | 46 | Swiss Cancer InstituteOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT04986670 | NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer | active not recruiting | N/A | 299 | Tufts UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07200154 | Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 23 | AmgenINDUSTRY | 6 | Sep 29, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT03041311 | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | completed | Phase 2 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06838208 | Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | recruiting | Phase 2 | 56 | Anhui Provincial Cancer HospitalOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT06505824 | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06021483 | Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection | recruiting | — | 300 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07161882 | ALG-LungCancerRegistry (SAFRO2202)(SAFRO2202) | recruiting | — | 3,750 | Société Algérienne de Formation et de Recherche en OncologieOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07173244 | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | not yet recruiting | — | 300 | Tianjin First Central HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07173946 | Prospective Observational Study on ES-SCLC | not yet recruiting | — | 96 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT04221529 | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide(SPACE) | completed | Phase 2 | 70 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2025 | clinicaltrials |
| NCT07145333 | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms(Drug-SNP) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 10 | STCube, Inc.INDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 22, 2025source: clinicaltrials